Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects

Trial Profile

A Phase I Study Assessing Single and Multiple Doses of AT-527 in Healthy and HCV-Infected Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Nov 2018

At a glance

  • Drugs AT 527 (Primary)
  • Indications Hepatitis C
  • Focus Adverse reactions; Proof of concept
  • Sponsors Atea Pharmaceuticals
  • Most Recent Events

    • 09 Nov 2018 Results presented in the Atea pharmaceuticals media release.
    • 01 Oct 2018 Status changed from active, no longer recruiting to completed.
    • 31 May 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top